Xlife Sciences: Valuation Report 2022 confirms and emphasizes long-term portfolio potential

Xlife Sciences AG / Key word(s): Miscellaneous

27-Apr-2023 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Xlife Sciences AG (SIX: XLS) today published the full Valuation Report 2022, which values the company's portfolio as of the end of 2022. The valuation was carried out by the independent consultancy Cylad Experts and covers 20 of Xlife Sciences’ 26 project companies.[1] The valuation is primarily based on the risk-adjusted net present value (NPV), typically used in the life sciences industry. The key parameters used in the valuation process are the cost of capital and the development risks of the project companies.

The Valuation Report 2022 values the portfolio of Xlife Sciences as of 31 December 2022 in a range between CHF 576 million (previous year: CHF 574.1 million) and CHF 704.5 million (previous year: CHF 701.7 million).[2]

• The six project companies alytas therapeutics, Veraxa Biotech, inflamed pharma, Inventum Genetics, FUSE-AI and Lysatpharma account for 80 percent of this portfolio value.
• The “biotechnology/therapies” area thus contributes 54 percent of the portfolio value, the “technology platforms” area 29 percent.
• 53 percent of the valued portfolio is in the “proof of concept” phase, another 17 percent in the clinical development phase.

Oliver R. Baumann, CEO of Xlife Sciences, comments: “The Valuation Report 2022 confirms and emphasizes the long-term portfolio potential of Xlife Sciences. It shows that our focus on early to very early-stage projects – depending on the future development success of the individual project companies – offers high leverage potential for investors”.

Xlife Sciences’ full Valuation Report 2022 is available for download at www.xlifesciences.ch/en/news-and-key-figures in the “Financial Reports” section.

Financial calendar

AGM 2023                                June 20, 2023

Half-Year Report 2023             September 21, 2023

Contact

Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

Information for investors: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch

[1] The six project companies panmabs, XRNA Biotech, xprot, novaxomx, Novum Technologie and x-diagnostics were not assessed.

[2] The valuation range for 2022 was already communicated on 20 April 2022 in the Annual Report 2022.

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange